| Report Title | Price | Action |
|---|---|---|
| Tyrosine Protein Phosphatase Non Receptor Type 11 (Protein Tyrosine Phosphatase 1D or Protein Tyrosine Phosphatase 2C or SHP2 or SHPTP2 or SH PTP3 or PTPN11 or EC 3.1.3.48) - Drugs in Development, 2021
Tyrosine Protein Phosphatase Non Receptor Type 11 (Protein Tyrosine Phosphatase 1D or Protein Tyrosine Phosphatase 2C or SHP2 or SHPTP2 or SH PTP3 or ...
Published: Apr-2021 | No. of Pages: 50
|
$ 3000 | |
| Cells Expressing Melanoma Associated Antigen 4 (Cancer/Testis Antigen 1.4 or MAGE 4 Antigen or MAGE 41 Antigen or MAGE X2 Antigen or MAGEA4) - Drugs in Development, 2021
Cells Expressing Melanoma Associated Antigen 4 (Cancer/Testis Antigen 1.4 or MAGE 4 Antigen or MAGE 41 Antigen or MAGE X2 Antigen or MAGEA4) - Drugs i...
Published: Apr-2021 | No. of Pages: 45
|
$ 3000 | |
| Trans Activator Of Transcription (Tat) - Drugs in Development, 2021
Trans Activator Of Transcription (Tat) - Drugs in Development, 2021 Summary Trans Activator Of Transcription (Tat) - Drugs in Development, 2021 prov...
Published: Apr-2021 | No. of Pages: 30
|
$ 3000 | |
| Central Nervous System (CNS) Cancer (Oncology) - Drugs in Development, 2021
Central Nervous System (CNS) Cancer (Oncology) - Drugs in Development, 2021 Summary Central Nervous System (CNS) Cancer (Oncology) - Drugs in Develo...
Published: Apr-2021 | No. of Pages: 35
|
$ 2000 | |
| Enterovirus Infections (Infectious Disease) - Drugs in Development, 2021
Enterovirus Infections (Infectious Disease) - Drugs in Development, 2021 Summary Enterovirus Infections (Infectious Disease) - Drugs in Development,...
Published: Apr-2021 | No. of Pages: 55
|
$ 2000 | |
| Aromatic L Amino Acid Decarboxylase (AADC or Dopa Decarboxylase or DDC or EC 4.1.1.28) - Drugs in Development, 2021
Aromatic L Amino Acid Decarboxylase (AADC or Dopa Decarboxylase or DDC or EC 4.1.1.28) - Drugs in Development, 2021 Summary Aromatic L Amino Acid De...
Published: Apr-2021 | No. of Pages: 50
|
$ 3000 | |
| Cholinesterase (Butyrylcholinesterase or Acylcholine Acylhydrolase or Choline Esterase II or Pseudocholinesterase or BCHE or EC 3.1.1.8) - Drugs in Development, 2021
Cholinesterase (Butyrylcholinesterase or Acylcholine Acylhydrolase or Choline Esterase II or Pseudocholinesterase or BCHE or EC 3.1.1.8) - Drugs in De...
Published: Apr-2021 | No. of Pages: 45
|
$ 3000 | |
| Wilms Tumor Protein (WT33 or WT1) - Drugs in Development, 2021
Wilms Tumor Protein (WT33 or WT1) - Drugs in Development, 2021 Summary Wilms Tumor Protein (WT33 or WT1) - Drugs in Development, 2021 provides in de...
Published: Apr-2021 | No. of Pages: 45
|
$ 3000 | |
| Head And Neck Carcinoma (Oncology) - Drugs in Development, 2021
Head And Neck Carcinoma (Oncology) - Drugs in Development, 2021 Summary Head And Neck Carcinoma (Oncology) - Drugs in Development, 2021 provides an ...
Published: Apr-2021 | No. of Pages: 35
|
$ 2000 | |
| Epithelial Ovarian Cancer (Oncology) - Drugs in Development, 2021
Epithelial Ovarian Cancer (Oncology) - Drugs in Development, 2021 Summary Epithelial Ovarian Cancer (Oncology) - Drugs in Development, 2021 provides...
Published: Apr-2021 | No. of Pages: 300
|
$ 2500 | |
| B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021
B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021 Summary B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021 provides in depth analysis on ...
Published: Apr-2021 | No. of Pages: 50
|
$ 3000 | |
| Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI (NADH Dependent Enoyl ACP Reductase or Enoyl ACP Reductase or EC 1.3.1.9) - Drugs in Development, 2021
Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI (NADH Dependent Enoyl ACP Reductase or Enoyl ACP Reductase or EC 1.3.1.9) - Drugs in Development, 2...
Published: Apr-2021 | No. of Pages: 45
|
$ 3000 | |
| Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11) - Drugs in Development, 2021
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Re...
Published: Apr-2021 | No. of Pages: 80
|
$ 3000 | |
| POEMS Syndrome (Crow-Fukase Syndrome) (Oncology) - Drugs in Development, 2021
POEMS Syndrome (Crow-Fukase Syndrome) (Oncology) - Drugs in Development, 2021 Summary POEMS Syndrome (Crow-Fukase Syndrome) (Oncology) - Drugs in De...
Published: Apr-2021 | No. of Pages: 35
|
$ 2000 | |
| Exocrine Pancreatic Insufficiency (Gastrointestinal) - Drugs in Development, 2021
Exocrine Pancreatic Insufficiency (Gastrointestinal) - Drugs in Development, 2021 Summary Exocrine Pancreatic Insufficiency (Gastrointestinal) - Dru...
Published: Apr-2021 | No. of Pages: 30
|
$ 2000 | |
| Cells Expressing Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) - Drugs in Development, 2021
Cells Expressing Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1)...
Published: Apr-2021 | No. of Pages: 50
|
$ 3000 | |
| Fibroblast Growth Factor Receptor (FGFR or EC 2.7.10.1) - Drugs in Development, 2021
Fibroblast Growth Factor Receptor (FGFR or EC 2.7.10.1) - Drugs in Development, 2021 Summary Fibroblast Growth Factor Receptor (FGFR or EC 2.7.10.1)...
Published: Apr-2021 | No. of Pages: 45
|
$ 3000 | |
| Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Drugs in Development, 2021
Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Drugs in Development, 2021 Summary ...
Published: Apr-2021 | No. of Pages: 30
|
$ 3000 | |
| Small Intestine Cancer (Oncology) - Drugs in Development, 2021
Small Intestine Cancer (Oncology) - Drugs in Development, 2021 Summary Small Intestine Cancer (Oncology) - Drugs in Development, 2021 provides an ov...
Published: Apr-2021 | No. of Pages: 35
|
$ 2000 | |
| Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021
Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021 Summary Familial Chylomicronemia (Type I H...
Published: Apr-2021 | No. of Pages: 35
|
$ 2000 |